Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468182 · ClinicalTrials.gov registry record
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 24
- Enrollment target
NCT00468182 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 24 participants.
The verdict
NCT00468182 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
Interventions
- DRUG Interferon-beta 1b (Betaseron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468182
The ClinicalTrials.gov registry entry for NCT00468182 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon-beta 1b (Betaseron) is the first listed.
NCT00468182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468182 about?
NCT00468182 is a clinical study titled "Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis". The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
What is the current status of trial NCT00468182?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2007-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00468182?
The interventions under investigation include: Interferon-beta 1b (Betaseron) (DRUG).
Who is sponsoring clinical trial NCT00468182?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.